Experienced in L1 Syndrome

Dr. Stephan A. Grupp

Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
Experienced in L1 Syndrome
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephan Grupp is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Grupp is rated as an Experienced provider by MediFind in the treatment of L1 Syndrome. His top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Leukemia, Neuroblastoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 238 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of L1 Syndrome.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Geisinger
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Grupp has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: KTE-X19 Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1/Phase 2
Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure
Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Device
Study Phase: Not Applicable
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Prednisone
Study Phase: Phase 2
UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Enrollment Status: Active_not_recruiting
Publish Date: January 01, 2025
Intervention Type: Device
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)
A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: July 02, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Biological
Study Phase: Phase 2
A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631
A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Procedure, Biological, Other
Study Phase: Phase 3
View 9 Less Clinical Trials

238 Total Publications

Profile of a Pioneer: Carl H. June.
Profile of a Pioneer: Carl H. June.
Journal: Transplantation and cellular therapy
Published: May 07, 2025
Similar Doctors
Distinguished in L1 Syndrome
Dr. Stephen P. Hunger
Pediatric Hematology Oncology
Distinguished in L1 Syndrome
Dr. Stephen P. Hunger
Pediatric Hematology Oncology
3401 Civic Center Blvd, Childrens Hospital Of Philadelphia, 
Phila, PA 
 (0.1 miles away)
215-590-3535
Languages Spoken:
English

Stephen Hunger is a Pediatric Hematologist Oncology provider in Phila, Pennsylvania. Dr. Hunger is rated as a Distinguished provider by MediFind in the treatment of L1 Syndrome. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, L1 Syndrome, and Bone Marrow Transplant.

Advanced in L1 Syndrome
Dr. Sarah K. Tasian
Pediatric Hematology Oncology
Advanced in L1 Syndrome
Dr. Sarah K. Tasian
Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3535
Languages Spoken:
English
See accepted insurances

Sarah Tasian is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Tasian is rated as a Distinguished provider by MediFind in the treatment of L1 Syndrome. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), and L1 Syndrome.

Experienced in L1 Syndrome
Dr. Shannon L. Maude
Pediatric Hematology Oncology
Experienced in L1 Syndrome
Dr. Shannon L. Maude
Pediatric Hematology Oncology

Childrens Health Care Associates Inc

3401 Civic Ctr Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English

Shannon Maude is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Maude is rated as a Distinguished provider by MediFind in the treatment of L1 Syndrome. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and L1 Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grupp's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile